INNOVATE.

VALIDATE.

SOLVE.

FDA Breakthrough Device Designation.
Patented nVRT Technology.

INNOVATE.

VALIDATE.

SOLVE.

FDA Breakthrough Device Designation.
Patented nVRT Technology.

Lightbulb Icon

Groundbreaking Technology

Our patented technology utilizes non-invasive Vestibular Resonance Therapy (nVRT) to impact the vestibular system.

Medical Icon

First Vertigo Wearable

We are developing a noninvasive and easy-to-use wearable solution for chronic vertigo, which is suffered by over 11 million Americans.

Headband Icon

Non-Invasive, Non-Pharmacological

The compact, headworn wearable device requires no surgery, advanced patient calibration, or complex fittings.

Compact Icon

Designed To Be Safe

Through development and clinical studies, our device has been used on over 600 subjects, with zero reportable serious device-related adverse events.

Enroll Now!

At-home Vertigo Study

Enrollment is limited and there is no cost to you. The investigational device is a new wearable intended to manage the symptoms of vertigo. 

  • Age Range: 18-75
  • Enrollment: Approx. 50 days
  • Compensation: Up to $420

Working With

Working
With

Ford Logo
U.S. Air Force Logo
Land Rover Logo
Audi Logo

Latest News

Otolith Labs Rounds Out Executive Team with Hiring of Chief Clinical Officer

Otolith Labs Rounds Out Executive Team with Hiring of Chief Clinical Officer

Kevin Franck, PhD, MBA appointed as Otolith Labs’ Chief Clinical Officer.

Otolith Expands Leadership Team with CCO and New Board Member

Otolith Expands Leadership Team with CCO and New Board Member

Otolith appointed Dan Wagner as Chief Commercial Officer and Raphael Michel to Otolith’s Board of Directors.

Mark Cuban-Backed Otolith Labs Just Raised Another $20M

Mark Cuban-Backed Otolith Labs Just Raised Another $20M

Technical.ly interviews Otolith’s CEO Sam Owen about the pressing need for a new treatment option for chronic vertigo.

Otolith Receives FDA Breakthrough Device Designation

Otolith Receives FDA Breakthrough Device Designation

Otolith Labs announces closing of $3.3 Million in seed funding, as well as receiving “Breakthrough Device” Designation from FDA.

Connect with us

ISO13485 Certification

200 Massachusetts Ave NW, Floor 7, Washington, DC 20001

© 2024 Otolith Labs, Inc.